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Background-—Although clear evidence shows that chronic kidney disease is a predictor of cardiovascular events, death, and
accelerated coronary artery disease (CAD) progression, it remains unknown whether CAD is a predictor of progression of chronic
kidney disease to end-stage renal disease. We sought to assess whether CAD adds prognostic information to established
predictors of progression to dialysis in patients with chronic kidney disease, diabetes, and anemia.
Methods and Results-—Using the previously described Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
population, we compared baseline characteristics of patients with and without CAD. Cox proportional hazards models were used to
assess the association between CAD and the outcomes of end-stage renal disease and the composite of death or end-stage renal
disease. Of the 4038 patients, 1791 had a history of known CAD. These patients were older (mean age 70 versus 65 years,
P<0.001) and more likely to have other cardiovascular disease. CAD patients were less likely to have marked proteinuria (29%
versus 39%, P<0.001), but there was no signiﬁcant difference in estimated glomerular ﬁltration rate between the 2 groups. After
adjusting for age, sex, race, estimated glomerular ﬁltration rate, proteinuria, treatment group, and 14 other renal risk factors,
patients with CAD were signiﬁcantly more likely to progress to end-stage renal disease (adjusted hazard ratio 1.20 [95% CI 1.01–
1.42], P=0.04) and to have the composite of death or end-stage renal disease (adjusted hazard ratio 1.15 [95% CI 1.01–1.30],
P=0.03).
Conclusions-—In patients with chronic kidney disease, diabetes, and anemia, a history of CAD is an independent predictor of
progression to dialysis. In patients with diabetic nephropathy, a history of CAD contributes important prognostic information to
traditional risk factors for worsening renal disease. ( J Am Heart Assoc. 2016;5:e002850 doi: 10.1161/JAHA.115.002850)
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C ardiovascular disease is the leading cause of death inpatients with type 2 diabetes mellitus (T2DM)1,2 and in
those with chronic kidney disease (CKD).3 T2DM and CKD are
known independent risk factors for cardiovascular death, and
patients with CKD are more likely to die from cardiovascular
causes than to progress to end-stage renal disease (ESRD).3
The association between kidney disease and poor cardiovas-
cular outcomes has been demonstrated in several popula-
tions,4–6 and a meta-analysis showed that patients with an
estimated glomerular ﬁltration rate (eGFR) <60 mL/min per
1.73 m2 had higher all-cause and cardiovascular mortality
compared with patients with an eGFR >90 mL/min per
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1.73 m2. Furthermore, mortality increased with each incre-
mental decrease in eGFR.4
Diabetes increases the risk of cardiovascular disease
including coronary artery disease (CAD), stroke, peripheral
artery disease, and heart failure (HF).7 Several studies have
demonstrated that having diabetes alone is a cardiovascular
risk equivalent in terms of cardiovascular event rates.8,9 In
addition, diabetic patients with evidence of microalbuminuria
have a 2-fold increased risk of cardiovascular death, even in
the absence of nephropathy.10 Patients with CKD also have
higher rates of stroke, HF, and myocardial infarction3 as well
as cardiovascular death independent of diabetes status.11 The
National Kidney Foundation task force recognizes that
patients with both T2DM and CKD are at the highest risk
for the development of cardiovascular disease6 and advocates
aggressive cardiovascular risk management of these patients.
Although clear evidence shows that CKD is a predictor of
cardiovascular events and death3,11 and is associated with
accelerated CAD progression,12 the reverse has not been
examined. Speciﬁcally, it is not known whether CAD is an
independent predictor of progression of CKD to ESRD in
patients with T2DM. We compared renal outcomes and
mortality in patients with diabetic nephropathy in the Trial to
Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
according to history of known CAD.13
Methods
TREAT was a randomized placebo-controlled trial of darbepo-
etin alfa treatment in 4038 patients with CKD (GFR 20–
60 mL/min per 1.73 m2), anemia (hemoglobin ≤11.0 g/dL),
and T2DM. Patients were excluded if they had a recent
cardiovascular event or a history of renal transplantation.
Patients were randomized to placebo or darbepoetin with
dose adjusted to a hemoglobin level of 13.0 g/dL. Although
there was a signiﬁcant difference in the secondary outcome of
stroke, there were no signiﬁcant differences between the 2
groups in terms of the primary end points: time to the
composite of all-cause mortality, stroke, HF, myocardial
infarction, or hospitalization for acute myocardial ischemia
or the time to the composite of ESRD or all-cause mortality.13
This study was approved by an institutional review committee,
and the participants gave informed consent to participate in
TREAT.
Statistical Analysis
Our primary predictor was a history of known CAD, deﬁned as
a self-reported history of CAD with or without a history of
myocardial infarction, coronary artery bypass grafting, or
percutaneous coronary intervention, as described
previously.14 We assessed whether a history of CAD was
associated with the risk of ESRD, as deﬁned in TREAT.13
Because patients with CAD have a high propensity for death,
we also assessed the association of CAD with the composite
end point of ESRD or death. In addition, we examined the
association of CAD with cardiovascular and noncardiovascular
death. A total of 4038 patients were included in this analysis.
Variables that were collected in the baseline case report form
were used, excluding those with missing data, resulting in
4010 patients in the renal analysis (model 1) and 3877
patients in the death (all-cause, cardiovascular, and noncar-
diovascular) analysis (model 2).
Baseline characteristics were compared for the groups
with known CAD and no known CAD. For continuous
variables, a Student t test and a Wilcoxon rank sum test
were used to compare normal and non-normal variables,
respectively. For categorical variables, a chi-square test was
used.
Cox proportional hazards models were used to examine
the relationship between the predictor of interest and the
outcomes. We used previously published models for the
prediction of renal outcomes15 (model 1) and death16 (model
2), with some revisions. Model 2, which was originally used to
predict cardiovascular outcomes and death, included a
covariate for coronary heart disease.16 We excluded this
covariate from the current analysis because of overlap with
our primary predictor. Treatment group (darbepoetin versus
placebo) was included in model 2,16 as originally described,
and added to model 1.15 CAD was included in all models, and
duration of T2DM and systolic blood pressure were added to
model 1. The urine protein/creatinine ratio and ferritin were
log transformed, and C-reactive protein was included as a
categorical variable in the models.15,16
Within each model, the statistical strength of the predictive
contribution of the covariates to the outcomes of interest was
expressed as the chi-square statistic 2-sided P value. Stata/
SE version 11.1 (StataCorp LP) was used for all analyses.
Results
Of the 4038 patients included in these analyses, 1791 (44%)
had known CAD. Baseline characteristics of those with and
without known CAD are shown in Table 1. Patients with known
CADwere older, more likely to bemale, andmore likely than the
patients without known CAD to be of white race. As expected,
patients with known CAD were signiﬁcantly more likely to have
a history of cardiovascular as well as cerebrovascular disease.
Patients with knownCAD had signiﬁcantly lower blood pressure
(mean systolic blood pressure 134 versus 137 mm Hg;
P<0.001), lower hemoglobin A1c (7.2 versus 7.4; P<0.001),
and a lower mean low-density lipoprotein level (86.3 versus
DOI: 10.1161/JAHA.115.002850 Journal of the American Heart Association 2
CAD Predicts ESRD in Patients with Diabetic Nephropathy Sabe et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on July 25, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Table 1. Baseline Characteristics of Patients With and Without Known CAD
Variable Known CAD (n=1791) No Known CAD (n=2247) P Value
Demographics and exam
Age (y), mean (SD) 70 (9.0) 65 (11.0) <0.001
Male sex, n (%) 874 (48.8) 852 (37.9) <0.001
Race, n (%) <0.001
White 1301 (72.6) 1269 (56.5)
Black 292 (16.3) 523 (23.3)
Other 198 (11.1) 455 (20.3)
Smoking history <0.001
Never 901 (50.3) 1366 (60.8)
Current 79 (4.4) 125 (5.6)
Past 811 (45.3) 756 (33.6)
Blood pressure (mm Hg), mean (SD)
Systolic 134 (19.0) 137 (19.0) <0.001
Diastolic 71 (11.0) 73 (11.0) <0.001
BMI (kg/m2), mean (SD) 31.4 (6.9) 31.6 (7.8) 0.30
Medical history, n (%)
Cardiovascular disease
Angina 664 (37.1) 82 (3.7) <0.001
MI 741 (41.4) 0 N/A
HF 962 (53.7) 385 (17.1) <0.001
CABG 571 (31.9) 0 N/A
PCI 367 (20.5) 0 N/A
Valvular heart disease 243 (13.6) 105 (4.7) <0.001
AICD 53 (3.0) 4 (0.2) <0.001
Atrial fibrillation 309 (17.3) 116 (5.2) <0.001
Cerebrovascular disease
Stroke 276 (15.4) 171 (7.6) <0.001
TIA 162 (9.0) 103 (4.6) <0.001
Peripheral arterial disease 499 (27.9) 280 (12.5) <0.001
History of hypertension 1698 (94.8) 2033 (90.5) <0.001
History of AKI 218 (12.2) 177 (7.9) <0.001
Duration of diabetes (years), median (IQR) 15.9 (8.6, 22.7) 15.1 (8.1, 21.1) 0.001
Laboratory indices
Ferritin (lg/L), median (IQR) 132 (68, 253) 134 (66, 261) 0.90
Transferrin saturation, mean (SD) 0.24 (0.10) 0.24 (0.09) 0.35
BUN (mg/dL), mean (SD) 42.9 (17.6) 42.0 (16.6) 0.11
eGFR (/10 mL/min/1.73 m2), mean (SD) 35.2 (11.7) 35.1 (12.0) 0.93
Protein/creatinine ratio (g/g), median (IQR) 0.3 (0.1, 1.3) 0.5 (0.1, 2.3) <0.001
Proteinuria (protein/creatinine ratio >1 g/g), n (%) 523 (29.2) 874 (38.9) <0.001
Albumin (g/dL), mean (SD) 4.0 (0.4) 3.9 (0.5) <0.001
Hemoglobin (g/dL), mean (SD) 10.4 (1.0) 10.3 (1.0) 0.11
Hemoglobin A1c, mean (SD) 7.2 (1.4) 7.4 (1.6) <0.001
Continued
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95.4 mg/dL; P<0.001) than the patients without known CAD.
They were more likely to be taking an aldosterone receptor
antagonist, b-blocker, or statin but less likely to be on an
angiotensin-converting enzyme inhibitor or angiotensin recep-
tor blocker. Patients with known CAD were less likely to have
marked proteinuria, deﬁned as a urine protein/creatinine ratio
>1 (29% versus 39%; P<0.001), but there was no signiﬁcant
difference in eGFR between the 2 groups (P=0.93). The 2 groups
did not differ in terms of treatment with the original study drug,
darbepoetin (P=0.16).
Renal Outcomes
Of the 4038 patients analyzed, 668 (17%) developed ESRD
and 1270 (31%) had the composite of death or ESRD. Overall,
293 (16.4%) of the patients with known CAD and 375 (16.7%)
of those without known CAD developed ESRD. CAD was not
signiﬁcantly associated with progression to ESRD (unadjusted
hazard ratio [HR] 1.03, 95% CI 0.89–1.21) on univariate
analysis; however, after adjusting for the covariates in model
1, a history of known CAD was signiﬁcantly associated with
progression to ESRD (adjusted HR 1.20, 95% CI 1.01–1.42)
(Table 2). A strong confounder in model 1 was the log urine
protein/creatinine ratio, which was signiﬁcantly higher in the
patients without known CAD (Table 1). After adjustment for
this covariate alone, CAD emerged as a signiﬁcant predictor
of ESRD (adjusted HR 1.34, P<0.001).
ESRD or death occurred in 634 (35%) of patients with
known CAD and 636 (28%) of those without known CAD,
corresponding to a signiﬁcant increase in risk for the CAD
patients of either progressing to ESRD or dying (unadjusted
HR 1.32, 95% CI 1.18–1.47) (Figure). After adjusting for the
covariates in model 1, a history of known CAD remained a
signiﬁcant predictor of the composite renal outcome (ad-
justed HR 1.15, 95% CI 1.01–1.30) (Table 3).
All-Cause, Cardiovascular, and Noncardiovascular
Death
CAD was found to be a signiﬁcant predictor of all-cause death
(unadjusted HR 1.61, 95% CI 1.40–1.85), which occurred in
444 (25%) of the patients with known CAD and 363 (16%) of
those without known CAD. After adjusting for the variables in
model 2, CAD was no longer a signiﬁcant independent
predictor of mortality (adjusted HR 1.02, 95% CI 0.87–1.20).
A history of HF appeared to be a strong confounder in this
model. With exclusion of this single covariate from the model,
CAD remained a signiﬁcant predictor of all-cause death
Table 1. Continued
Variable Known CAD (n=1791) No Known CAD (n=2247) P Value
Total cholesterol (mg/dL), mean (SD) 170.6 (52.2) 182.8 (52.0) <0.001
LDL (mg/dL), mean (SD) 86.3 (38.2) 95.4 (40.7) <0.001
HDL (mg/dL), mean (SD) 46.3 (13.8) 49.8 (15.7) <0.001
Triglycerides (mg/dL), median (IQR) 153 (108, 227) 156 (111, 233) 0.19
CRP category, n (%) 0.02
≤3.0 mg/dL 894 (49.9) 1218 (54.2)
>3.0 to <6.6 mg/dL 426 (23.8) 480 (21.4)
≥6.6 mg/dL 471 (26.3) 549 (24.4)
Medications, n (%)
Insulin 896 (50.3) 1093 (48.6) 0.38
Oral hypoglycemic (oral antidiabetic agents) 1002 (55.9) 1291 (57.5) 0.34
ACEI or ARB 1388 (77.5) 1835 (81.7) <0.001
Beta blocker 1131 (63.1) 859 (38.2) <0.001
Aldosterone receptor antagonist 139 (7.8) 70 (3.1) <0.001
Statin 1200 (67.0) 1164 (51.8) <0.001
Aspirin 934 (52.1) 779 (34.7) <0.001
Oral iron 1211 (67.7) 1388 (61.9) <0.001
Treatment with darbepoetin, n (%) 870 (48.6) 1142 (50.8) 0.16
ACEI indicates angiotensin converting enzyme inhibitor; AICD, automatic implantable cardioverter deﬁbrillator; AKI, acute kidney injury; ARB, angiotensin receptor blocker; BMI, body mass
index; BUN, blood urea nitrogen; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; HDL, high-density
lipoprotein; HF, heart failure; IQR, interquartile range; LDL, low-density lipoprotein; MI, myocardial infarction; N/A, not available; PCI, percutaneous coronary intervention; TIA, transient
ischemic attack.
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(adjusted HR 1.18, P=0.035). Similarly, CAD was a signiﬁcant
predictor of cardiovascular death (unadjusted HR 1.91, 95% CI
1.60–2.28); however, it became nonsigniﬁcant after adjust-
ment using model 2 (adjusted HR 1.21, 95% CI 0.99–1.48).
Again, a history of HF was a strong confounder in this model.
Sensitivity Analysis: Angina
To assess whether our results changed signiﬁcantly with
inclusion of these patients, we reanalyzed the models after
including 82 patients from TREAT who gave a self-reported
history of angina without a history of CAD, myocardial
infarction, coronary artery bypass grafting, or percutaneous
coronary intervention. Inclusion of these patients slightly
strengthened the relationship between CAD and progression
to ESRD (adjusted HR 1.22, 95% CI 1.03–1.45) and the renal
composite outcome (adjusted HR 1.17, 95% CI 1.03–1.32)
(Tables 4 and 5).
Discussion
We found that in patients with CKD, T2DM, and anemia, the
presence of known CAD was independently predictive of
progression of CKD to ESRD. Contrary to previous studies
which suggest an association between proteinuria and CAD,17,18
in our study patients with CAD had signiﬁcantly less proteinuria
than those without CAD. It is not clear why these patients had
less proteinuria despite taking fewer angiotensin receptor
blockers or angiotensin-converting enzyme inhibitors. One
possibility is that the patients with CAD were more likely to
Table 2. Multivariable Models for Renal Outcomes
Variable
ESRD ESRD or Death
HR (95% CI) P Value HR (95% CI) P Value
Known CAD 1.20 (1.01–1.42) 0.041 1.15 (1.01–1.30) 0.031
Age 1.00 (0.99–1.00) 0.432 1.02 (1.01–1.02) <0.001
Male sex 1.69 (1.44–1.99) <0.001 1.42 (1.26–1.59) <0.001
Race (referent: white)
Black 1.72 (1.43–2.08) <0.001 1.27 (1.10–1.47) 0.001
Other 1.00 (0.81–1.25) 0.966 0.92 (0.77–1.08) 0.312
BMI, per 10 kg/m2 0.81 (0.71–0.92) 0.001 0.80 (0.74–0.88) <0.001
Insulin use 1.15 (0.97–1.36) 0.112 1.14 (1.00–1.29) 0.042
eGFR, per 10 mL/min/1.73 m2 0.52 (0.47–0.58) <0.001 0.77 (0.71–0.82) <0.001
BUN, per 10 mg/dL 1.12 (1.06–1.17) <0.001 1.08 (1.04–1.13) <0.001
Log (UPCR) 1.87 (1.73–2.02) <0.001 1.42 (1.35–1.49) <0.001
Albumin, per 1 g/dL 0.70 (0.58–0.84) <0.001 0.61 (0.53–0.70) <0.001
Prior stroke 1.17 (0.91–1.50) 0.211 1.30 (1.11–1.53) 0.002
Prior PAD 1.10 (0.90–1.35) 0.355 1.13 (0.98–1.30) 0.084
Prior HF 1.30 (1.09–1.56) 0.004 1.49 (1.31–1.69) <0.001
History of arrhythmia 1.17 (0.93–1.48) 0.189 1.27 (1.09–1.48) 0.002
Hemoglobin, per 1 g/dL 0.95 (0.88–1.03) 0.188 0.95 (0.90–1.00) 0.073
Log (ferritin) 1.10 (1.01–1.19) 0.030 1.04 (0.98–1.11) 0.202
CRP (referent: ≤3.0 mg/L)
CRP 3.1–6.5 mg/L 1.13 (0.93–1.37) 0.229 1.16 (1.00–1.34) 0.044
CRP ≥6.6 mg/L 1.31 (1.08–1.58) 0.006 1.42 (1.24–1.63) <0.001
History of acute kidney injury 1.32 (1.05–1.66) 0.019 1.22 (1.03–1.45) 0.023
Systolic blood pressure 1.00 (1.00–1.01) 0.248 1.00 (1.00–1.00) 0.763
Duration of T2DM 1.00 (1.00–1.00) 0.109 1.00 (1.00–1.00) 0.835
Treatment with darbepoetin 1.08 (0.93–1.26) 0.321 1.12 (1.00–1.25) 0.044
BMI indicates body mass index; BUN, blood urea nitrogen; CAD, coronary artery disease; CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; ESRD, end-stage renal disease;
HF, heart failure; HR, hazard ratio; PAD, peripheral artery disease; T2DM, type 2 diabetes mellitus; UPCR, urine protein/creatinine ratio.
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be of white race, and proteinuria occurs more frequently in non-
whites.19,20 Another reason may be that the patients with CAD
were on more aldosterone receptor antagonists, which have
been shown to be associated with a decrease in proteinuria.21
Despite having less proteinuria, the patients with CAD had a
higher propensity for progression to dialysis after adjusting for
risk factors for dialysis including proteinuria and eGFR. These
results suggest that in patients with CKD, a history of CAD can
augment the prognostic information provided by traditional risk
factors for renal disease progression.
According to the US Renal Data System 2013 Annual Data
Report, the incidence of ESRD in 2011 was 357 per 1 million
population, and >100 000 patients started therapy for ESRD
in 2011 alone, representing a 1.5% increase from the
previous year.22 Patients on hemodialysis have twice the
mortality rate of the general population with diabetes, CAD,
cancer, HF, or stroke and 10 times the mortality rate of
similarly aged patients without CKD.22 Overall, 40% of
patients with T2DM develop CKD, and T2DM is the most
frequent cause of ESRD.23 In addition, evidence shows that
anemia is a risk factor that may contribute to the progression
of diabetic nephropathy to ESRD.24 Because progression of
renal injury in patients with CKD with or without diabetes is
quite variable, early identiﬁcation of risk factors that
contribute to renal loss can be important for risk stratiﬁcation
and treatment.23,25
Figure. The association between CAD, proteinuria, eGFR and renal outcomes. A history of known CAD contributes to proteinuria and eGFR as a
risk factor for progression to ESRD and ESRD or death. Proteinuria is represented as a categorical variable divided at a PCR of 1. eGFR is
represented as a categorical variable divided at the median, 33.8 mL/min per 1.73 m2. An interaction term for CAD and proteinuria was added
to the ﬁnal renal multivariable model and found to be nonsigniﬁcant for the outcomes of ESRD (P=0.23) and ESRD or death (P=0.10). Similarly,
the interaction terms for eGFR and CAD were found to be nonsigniﬁcant in the ﬁnal multivariable model for both outcomes (ESRD, P=0.44; ESRD
or death, P=0.59). CAD indicates coronary artery disease; eGFR, estimated glomerular ﬁltration rate; ESRD, end-stage renal disease; PCR,
protein/creatinine ratio.
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Vascular calciﬁcation has been implicated as the patho-
physiological link between CKD and CAD,26 and some studies
have suggested that coronary artery calcium scores are
associated with increasing severity of kidney disease. The
Chronic Renal Insufﬁciency Cohort study demonstrated a
graded association between coronary artery calcium and the
severity of CKD after adjusting for traditional risk factors.27
Furthermore, coronary artery calcium scores >100 were
signiﬁcantly more common in patients with CKD and diabetes
than in those with CKD alone.27 Garland et al prospectively
followed 125 predialysis patients for decline in kidney
function and found that, compared with a score of 0, a
coronary artery calcium score of 100 to 399 was associated
with 7.4 increased odds of a decline in kidney function, and a
score >400 was associated with 8.8 increased odds of kidney
function decline at 1 year of follow-up.28 Nevertheless, it is
not clear whether vascular calciﬁcation is a cause of
worsening renal function.
There are a few possible explanations for the observed
association between baseline CAD and subsequently worsen-
ing renal disease in patients with diabetes. The progression of
diabetic nephropathy is marked by accumulation of extracel-
lular matrix, tubulointersitial ﬁbrosis, tubular arteriosclerosis,
and abnormal podocyte morphology,29 and inﬂammation may
play an important role. Sun et al found in an animal model that
coronary artery stenosis increased renal oxidative stress,
ﬁbrosis, inﬂammation, tubular injury, and microvasculature
remodeling.30 Circulating matrix metalloproteinases, which
may contribute to renal ﬁbrosis, are elevated in CAD and have
been implicated as a poor prognostic indicator in these
patients.31,32 Hsu et al showed that in patients with CAD,
circulating matrix metalloproteinases are independently asso-
ciated with renal disease progression.33 This association was
seen in nondiabetic patients but also may be an important link
in the diabetic population. Bleyer et al suggested an associ-
ation between atherosclerosis and progression of renal
disease using carotid intimal thickness.34 It is possible that
patients with extrarenal atherosclerosis may have renal
vasculature arteriosclerosis causing worsening renal disease.
Clinical factors should also be considered in the observed
relationship between CAD and renal decline. HF may con-
tribute to renal progression in patients with CAD, and although
we found that CAD was independently associated with
worsening renal function independent of a history of HF, it is
not known whether these patients had subsequent episodes of
HF after the baseline assessment. Another consideration is
that patients with CAD may have a greater risk of progressive
renal injury related to contrast administration from invasive
angiography; however, we tested this hypothesis by including
a time-varying covariate for coronary revascularization in the
models and found that coronary revascularization was not
signiﬁcantly associated with renal disease progression and
had a negligible effect on the relationship between known CAD
and renal disease progression.
In terms of mortality, we found that known CAD was not
associated with all-cause or cardiovascular death independent
of a history of HF, suggesting that death caused by CAD in
patients with CKD may be predominantly inﬂuenced by a
Table 3. Association Between Known CAD and Outcomes
Outcome
Participants With Event, n (%), Incidence Rate Per
100 Person-Years
Unadjusted HR (95% CI)
P Value
Adjusted HR (95% CI)
P ValueKnown CAD (n=1791) No Known CAD (n=2247)
Model 1*
ESRD 293 (16.4%)
7.5/100
375 (16.7%)
7.3/100
1.03 (0.89–1.21)
0.66
1.20 (1.01–1.42)
0.04
Death or ESRD 634 (35.4%)
15.9/100
636 (28.3%)
12.1/100
1.32 (1.18–1.47)
<0.001
1.15 (1.01–1.30)
0.03
Model 2†
All-cause death 444 (24.8%)
10.3/100
363 (16.2%)
6.4/100
1.61 (1.40–1.85)
0.001
1.02 (0.87–1.20)
0.78
Noncardiovascular death 143 (8.0%)
3.3/100
155 (6.9%)
2.7/100
1.21 (0.96–1.52)
0.10
0.77 (0.60–1.00)
0.046
Cardiovascular death 301 (16.8%)
7.0/100
208 (9.3%)
3.7/100
1.91 (1.60–2.28)
<0.001
1.21 (0.99–1.48)
0.06
CAD indicates coronary artery disease; ESRD, end-stage renal disease; HR, hazard ratio.
*Model 1 covariates: age, sex, race, body mass index, insulin use, estimated glomerular ﬁltration rate, blood urea nitrogen, log urine protein/creatinine ratio, albumin, history of stroke,
history of peripheral artery disease, history of heart failure, arrhythmia, hemoglobin, log ferritin, C-reactive protein, history of acute renal failure, duration of diabetes, systolic blood
pressure, and treatment with darbepoetin (renal model,15 plus duration of type 2 diabetes mellitus, systolic blood pressure, and treatment with darbepoetin).
†Model 2 covariates: age, race, sex, history of heart failure, log urine protein/creatinine ratio, C-reactive protein, abnormal ECG, serum albumin, arrhythmia, hemoglobin A1c, reticulocytes,
blood urea nitrogen, insulin use, cerebrovascular disease, loop diuretics, hemoglobin level, and treatment with darbepoetin (cardiovascular model).14
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history of HF. In contrast, CAD is predictive of noncardiovas-
cular death after adjustment for HF. Bauters et al corrobo-
rated the importance of HF by showing that the strongest
predictor of mortality in patients with stable CAD is a history
of HF hospitalization.35 Furthermore, Parfrey et al found that
ischemic heart disease was not a predictor of mortality in
dialysis patients independent of HF.36
This study has some limitations. This is a secondary
analysis of TREAT, a randomized controlled trial of darbepo-
etin treatment in patients with anemia, T2DM, and CKD that
included patients with eGFR of 20 to 60 mL/min per
1.73 m2. It is possible that our results would change if we
included patients with a broader range of eGFRs. In addition,
we found known CAD to be predictive of renal events in
patients with T2DM, CKD, and anemia, but these ﬁndings may
not be generalizable to CKD patients without T2DM and
anemia. Furthermore, the deﬁnition of ESRD in this study was
based on the subjective decision of the clinician and not
necessarily on the eGFR or rate of deterioration of eGFR.
Another potential limitation is that because CAD was self-
reported, there may be patients with underlying CAD (eg,
asymptomatic myocardial ischemia) who were misclassiﬁed
as having no CAD. This issue of possible misclassiﬁcation was
partially addressed in TREAT because the investigators
individually reviewed all forms and patients were reclassiﬁed
if discrepancies were found, such as a patient reporting a
history of coronary artery bypass grafting but no history of
CAD. Nevertheless, 3% of patients without self-reported CAD
underwent cardiac revascularization during the follow-up
period of TREAT. Although this ﬁnding may suggest misclas-
siﬁcation of some of the non-CAD patients, it may also be
consistent with previous data showing that even CKD patients
Table 4. Multivariable Model for Renal Outcomes After Including Patients With Angina
Variable
ESRD Model ESRD or Death
HR (95% CI) P Value HR (95% CI) P Value
Known CAD 1.22 (1.03–1.45) 0.023 1.17 (1.03–1.32) 0.017
Age 1.00 (0.99–1.00) 0.411 1.02 (1.01–1.02) <0.001
Male sex 1.69 (1.44–1.99) <0.001 1.41 (1.26–1.59) <0.001
Race (referent: white)
Black 1.72 (1.43–2.08) <0.001 1.27 (1.10–1.47) 0.001
Other 1.01 (0.81–1.25) 0.0 0.92 (0.78–1.09) 0.318
BMI, per 10 kg/m2 0.81 (0.71–0.92) 0.001 0.80 (0.74–0.88) <0.001
Insulin use 1.15 (0.97–1.36) 0.117 1.14 (1.00–1.29) 0.043
eGFR, per 10 mL/min/1.73 m2 0.52 (0.47–0.59) <0.001 0.77 (0.71–0.82) <0.001
BUN, per 10 mg/dL 1.12 (1.06–1.17) <0.001 1.09 (1.05–1.13) <0.001
Log (UPCR) 1.87 (1.73–2.02) <0.001 1.42 (1.35–1.49) <0.001
Albumin, per 1 g/dL 0.70 (0.58–0.84) <0.001 0.61 (0.53–0.70) <0.001
Prior stroke 1.16 (0.91–1.49) 0.231 1.30 (1.10–1.53) 0.002
Prior PAD 1.10 (0.90–1.34) 0.368 1.13 (0.98–1.30) 0.085
Prior HF 1.29 (1.08–1.54) 0.005 1.48 (1.30–1.68) <0.001
History of arrhythmia 1.17 (0.92–1.47) 0.198 1.27 (1.09–1.47) 0.002
Hemoglobin, per 1 g/dL 0.95 (0.88–1.03) 0.190 0.95 (0.9–1.01) 0.074
Log (ferritin) 1.10 (1.01–1.20) 0.029 1.04 (0.98–1.11) 0.195
C-reactive protein (referent: ≤3.0 mg/L)
CRP 3.1–6.5 mg/L 1.13 (0.93–1.37) 0.232 1.16 (1.00–1.34) 0.044
CRP ≥6.6 mg/L 1.31 (1.08–1.59) 0.006 1.42 (1.24–1.63) <0.001
History of AKI 1.31 (1.04–1.65) 0.021 1.22 (1.03–1.44) 0.024
Systolic blood pressure 1.00 (1.00–1.01) 0.252 1.00 (1.00–1.00) 0.758
Duration of T2DM 1.00 (1.00–1.00) 0.113 1.00 (1.00–1.00) 0.855
Treatment with darbepoetin 1.08 (0.92–1.26) 0.340 1.12 (1.00–1.25) 0.048
AKI indicates acute kidney injury; BMI, body mass index; BUN, blood urea nitrogen; CAD, coronary artery disease; CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; ESRD,
end-stage renal disease; HF, heart failure; HR, hazard ratio; PAD, peripheral artery disease; T2DM, type 2 diabetes mellitus; UPCR, urine protein/creatinine ratio.
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with normal initial coronary angiography might have higher
rates of acute myocardial infarction during 3-year follow-up,
suggesting accelerated coronary atherosclerosis in these
patients.37 Patients who reported angina but not CAD were
not included as CAD patients in TREAT; therefore, we conducted
a sensitivity analysis of our results by including those patients
who reported angina without CAD and found that the associ-
ation between CAD and renal outcomes and cardiovascular
death was actually strengthened by including these patients.
Another important limitation of this study is that patients were
censored at the time of death, which is a competing risk, in the
model assessing the outcome of ESRD alone. Finally, although
an association between peripheral artery disease and worsening
renal function was demonstrated previously,38 we did not ﬁnd
peripheral artery disease to be an independent predictor of
ESRD. Since less than 25% of the TREAT cohort had a history of
peripheral artery disease, this study may not have been
powered to detect a signiﬁcant association.
In this study of patients with CKD and T2DM, we found that
a history of known CAD was an independent predictor of
ESRD and the composite of death or ESRD. Because CAD is a
known predictor of death, we also assessed the association
between CAD and ESRD alone and found that known CAD was
an independent risk factor for the progression of CKD to ESRD
in this study population. Consequently, patients with diabetic
nephropathy and CAD may be a particularly high-risk group
not only in terms of cardiovascular disease but also in terms
of renal disease progression. Consequently, CAD should be
considered an important factor in the risk stratiﬁcation of
these patients. A continued cooperative effort among cardi-
ologists and nephrologists will be necessary to prevent further
disease progression of these interrelated organ systems and,
ultimately, to optimize the care of these complicated
patients.
Disclosures
Sabe: none; Claggett: none; Burdmann: Research Grant:
Amgen, Roche. Consultant/Advisory Board: Amgen, Sigma
Pharma; Desai: Research support: Amgen; Ivanovich: Consul-
tant/Advisory Board: Amgen, Baxter, Physician Software
Systems, LLC, Reata; Kewalramani: Employment: Amgen.
Ownership Interest: Amgen; Lewis: Research Grant: Amgen;
McMurray: none; Olson: Employment: Amgen. Ownership
Interest: Amgen; Parfrey: Honoraria: Amgen. Consultant/
Advisory Board: Amgen; Solomon: Research Grant: Amgen.
Consultant/Advisory Board: Amgen; Pfeffer: Research Grant:
Amgen, Celladon, Novartis, Sanoﬁ Aventis; Ownership Inter-
est: coinventor on a patent for the use of inhibitors of the
renin-angiotensin system in selected survivors of myocardial
infarction, his share is transferred to charity. Consultant/
Advisory Board: Aastrom, Abbott Vascular, Amgen, Bristol-
Myers Squibb, Cerenis, Concert, Fibrogen, Genzyme,
GlaxoSmithKline, Hamilton Health Sciences, Medtronic, Mer-
ck, Novo Nordisk, Roche, Salix, Sanderling, Serono, Servier,
Teva, University of Oxford.
Table 5. Association Between Known CAD and Outcomes After Including Patients With Angina
Outcome
Participants With Event, n (%), Incidence Rate Per
100 Person-Years
Unadjusted Model
HR (CAD vs No CVD), 95% CI, P Value
Adjusted Model
HR (CAD vs No CVD), 95% CI, P ValueKnown CAD (n=1873) No Known CAD (n=2165)
Model 1*
ESRD 308 (16.4%)
7.5/100
360 (16.6%)
7.3/100
1.03 (0.89–1.20)
0.67
1.22 (1.03–1.45)
0.02
Renal composite 662 (35.3%)
15.8/100
608 (28.1%)
12.1/100
1.31 (1.17–1.46)
<0.001
1.17 (1.03–1.32)
0.02
Model 2†
All-cause death 466 (24.9%)
10.3/100
341 (15.8%)
6.3/100
1.65 (1.43–1.89)
0.001
1.07 (0.92–1.26)
0.38
Noncardiovascular death 150 (8.0%)
3.3/100
148 (6.8%)
2.7/100
1.22 (0.97–1.53)
0.09
0.79 (0.62–1.02)
0.08
Cardiovascular death 316 (16.9%)
7.0/100
193 (8.9%)
3.6/100
1.98 (1.65–2.36)
<0.001
1.29 (1.06–1.59)
0.01
With inclusion of these 82 patients, CAD was no longer signiﬁcantly associated with a decreased risk of noncardiovascular death (adjusted HR 0.79, 95% CI 0.62–1.02); however, addition
of these patients strengthened the relationship between CAD and cardiovascular death, ESRD, and the composite renal outcome. CAD indicates coronary artery disease; ESRD, end-stage
renal disease; HR, hazard ratio.
*Model 1 covariates: age, sex, race, body mass index, insulin use, estimated glomerular ﬁltration rate, blood urea nitrogen, log urine protein/creatinine ratio, albumin, history of stroke,
history of peripheral artery disease, history of heart failure, arrhythmia, hemoglobin, log ferritin, C-reactive protein, history of acute renal failure, duration of diabetes, systolic blood
pressure, and treatment with darbepoetin (renal model,15 plus duration of type 2 diabetes mellitus, systolic blood pressure, and treatment with darbepoetin).
†Model 2 covariates: age, race, sex, history of heart failure, log urine protein/creatinine ratio, C-reactive protein, abnormal ECG, serum albumin, arrhythmia, hemoglobin A1c, reticulocytes,
blood urea nitrogen, insulin use, cerebrovascular disease, loop diuretics, hemoglobin level, and treatment with darbepoetin (cardiovascular model).14
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